Overview


Animal insulin is an injectable drug obtained from animal sources to help individuals with insulin-dependent diabetes in managing their blood sugar levels. It is structurally similar to human insulin, but there is a difference in the amino acid sequence. Animal insulin is derived from the pancreas of animals, usually pigs and cows, and was the primary insulin therapy option until the 1980s. After the insulin extraction from these animals, it is purified to lower the risk of an allergic reaction. Animal insulin is available as a prescribed drug. Animal insulin comes in various types, classified based on their speed of action in regulating blood glucose levels. These types include porcine insulin, derived from pigs, and bovine insulin, sourced from cows.

Bovine Insulin is a significant variant within the type of animal-derived insulins. Bovine Insulin, also known as beef insulin, is a two-chain polypeptide hormone produced in vivo in the pancreatic β cells. It regulates glucose uptake into muscle and fat cells by mobilization of the membrane glucose transporter Glut-4 to the cell surface. Bovine Insulin is often used as a growth supplement in culturing cells at concentrations ranging from 1 to 10 micrograms per milliliter of medium. The amino acid sequence of Insulin is exceptionally well preserved. Bovine Insulin differs from human Insulin in only three amino acid residues, similar enough to be clinically effective in humans. Bovine Insulin also influences other body functions, such as vascular compliance and cognition. Insulin enhances learning and memory once it enters the human brain and benefits verbal memory.

FutureWise Market Research has published a report that provides an insightful analysis animal insulin market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. According to the analysis conducted by FutureWise research analysts, animal insulin market is estimated to register a considerable growth rate over the forecast period. This report lists the market segments and potential prospects available across this industry, in addition providing crucial information on the total valuation currently held by the industry. Moreover, this report will assist key management individuals in an organisation to enhance their decisions pertaining to business expansion as well as strategic changes for increasing customer base.

  • Eli Lilly
  • Novo Nordisk
  • Sanofi
  • Tonghua Dongbao
  • Ganlee
  • Merck
  • Wockhardt
  • MannKind Corporation
  • Boehringer Ingelheim
  • Zhuhai United Laboratries Co.

(Note: The list of the major players will be updated with the latest market scenario and trends)

The increasing prevalence of diabetes cases among pets, especially cats and dogs, is expected to drive the demand for the animal insulin market. This concerning occurrence is primarily attributed to the prevalence of sedentary lifestyles and growing obesity rates in companion animals. Pets, like humans, are increasingly exposed to a more stagnant environment, indicated by reduced physical activity levels and increased calorie intake. This lifestyle change has contributed to an increased incidence of obesity, a well-established risk factor for diabetes. As more pet owners become aware of these health considerations, there is a rising demand for specialized treatment solutions, such as insulin, to effectively manage and treat diabetes in their furry companions. Moreover, the rising incidences of pet ownership, particularly in urbanized areas, are propelling the demand for animal healthcare products, with insulin at the forefront. Urbanization has led to smaller living spaces and busy lifestyles, compelling a growing preference for smaller companion pets like cats and dogs. This surge in pet companionship has elevated pet owners' awareness of their animals' health needs, facilitating a culture of responsible pet ownership and further driving the growth of the animal insulin market over the forecast period. However, the slaughtering of a large number of animals, especially for the extraction of porcine and bovine insulin, presents a significant ethical and environmental restraint on the market. This raises concerns over animal welfare and ethical treatment, sparkling debates on more sustainable and humane alternatives in insulin production. Furthermore, the environmental effect of large-scale animal farming and slaughterhouses is a growing concern about land use, water consumption, and greenhouse gas emissions. These ethical and environmental difficulties pose a substantial challenge to the animal insulin market, provoking the industry to explore and invest in alternatives for more sustainable production methods.

By Product

  • Porcine Insulin
  • Bovine Insulin

By Application

  • Humna
  • Animals

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of region will also be provided in the final version of this market which is based on conclusion of primary interviews and secondary data point gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America registered highest share in the market in 2022. Owing to factors such as the increase in diabetic patients, a rise in examination exercises in the district and arrangement of different makers, the growing geriatric population, rising healthcare expenditure, rising research activities, and rising mindfulness among individuals with respect to the advantages of insulin contribute toward the animal insulin market growth in the region. Additionally, an increase in the number of veterinarians and technological advances in the field of diabetes management are anticipated to fuel the growth of the animal insulin market over the forecast period.

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Animal Insulin Market By Product, By Application and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Animal Insulin Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Type Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Animal Insulin Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Animal Insulin Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Type Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Type Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Animal Insulin Market, By Product Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Porcine Insulin
        2. Bovine Insulin

  • 8.   Animal Insulin Market, By Application Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Humna
        2. Animals

  • 9.   North America Animal Insulin Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 10.   Latin America Animal Insulin Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 11.   Europe Animal Insulin Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 12.   Asia Pacific Animal Insulin Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 13.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 14.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 15.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Eli Lilly
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Novo Nordisk
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Sanofi
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Tonghua Dongbao
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Ganlee
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Merck
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Wockhardt
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. MannKind Corporation
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Boehringer Ingelheim
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. Zhuhai United Laboratries Co.
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview

  • 16.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by administrations
        5. The overall economic slowdown of the developing and developed nations
  • 17.   FutureWise SME Key Takeaway Points for Client

Related Market

Human Insulin Market

Read More

Human Insulin Drugs and Delivery Devices Market

Read More

Premix Insulin Market

Read More
Partner

Our Clients